48,702
edits
(more) |
|||
(3 intermediate revisions by the same user not shown) | |||
Line 7: | Line 7: | ||
| Micro = | | Micro = | ||
| Subtypes = | | Subtypes = | ||
| LMDDx = [[anal intraepithelial neoplasia]] | | LMDDx = [[anal intraepithelial neoplasia]], poorly differentiated [[rectal adenocarcinoma]], [[anal gland adenocarcinoma]] | ||
| Stains = | | Stains = | ||
| IHC = | | IHC = p16 +ve | ||
| EM = | | EM = | ||
| Molecular = | | Molecular = HPV +ve | ||
| IF = | | IF = | ||
| Gross = | | Gross = | ||
Line 50: | Line 50: | ||
DDx: | DDx: | ||
*[[Anal intraepithelial neoplasia]]. | *[[Anal intraepithelial neoplasia]]. | ||
*Rectal squamous cell carcinoma.<ref name=pmid17661147>{{Cite journal | last1 = Nahas | first1 = CS. | last2 = Shia | first2 = J. | last3 = Joseph | first3 = R. | last4 = Schrag | first4 = D. | last5 = Minsky | first5 = BD. | last6 = Weiser | first6 = MR. | last7 = Guillem | first7 = JG. | last8 = Paty | first8 = PB. | last9 = Klimstra | first9 = DS. | title = Squamous-cell carcinoma of the rectum: a rare but curable tumor. | journal = Dis Colon Rectum | volume = 50 | issue = 9 | pages = 1393-400 | month = Sep | year = 2007 | doi = 10.1007/s10350-007-0256-z | PMID = 17661147 }}</ref> | |||
*Poorly differentiated [[rectal adenocarcinoma]]. | *Poorly differentiated [[rectal adenocarcinoma]]. | ||
*[[Anal gland adenocarcinoma]]. | *[[Anal gland adenocarcinoma]]. | ||
Line 64: | Line 65: | ||
*CDX2 -ve/+ve. | *CDX2 -ve/+ve. | ||
**May be useful to differentiate from [[vulva]] and [[penis]].<ref name=pmid23105122>{{Cite journal | last1 = Gunia | first1 = S. | last2 = Koch | first2 = S. | last3 = May | first3 = M. | title = Is CDX2 immunostaining useful for delineating anorectal from penile/vulvar squamous cancer in the setting of squamous cell carcinoma with clinically unknown primary site presenting with histologically confirmed inguinal lymph node metastasis? | journal = J Clin Pathol | volume = 66 | issue = 2 | pages = 109-12 | month = Feb | year = 2013 | doi = 10.1136/jclinpath-2012-201138 | PMID = 23105122 }}</ref> | **May be useful to differentiate from [[vulva]] and [[penis]].<ref name=pmid23105122>{{Cite journal | last1 = Gunia | first1 = S. | last2 = Koch | first2 = S. | last3 = May | first3 = M. | title = Is CDX2 immunostaining useful for delineating anorectal from penile/vulvar squamous cancer in the setting of squamous cell carcinoma with clinically unknown primary site presenting with histologically confirmed inguinal lymph node metastasis? | journal = J Clin Pathol | volume = 66 | issue = 2 | pages = 109-12 | month = Feb | year = 2013 | doi = 10.1136/jclinpath-2012-201138 | PMID = 23105122 }}</ref> | ||
*PD-L1 +ve in ~40% of cases.<ref name=pmid34790403>{{cite journal |authors=Armstrong SA, Malley R, Wang H, Lenz HJ, Arguello D, El-Deiry WS, Xiu J, Gatalica Z, Hwang JJ, Philip PA, Shields AF, Marshall JL, Salem ME, Weinberg BA |title=Molecular characterization of squamous cell carcinoma of the anal canal |journal=J Gastrointest Oncol |volume=12 |issue=5 |pages=2423–2437 |date=October 2021 |pmid=34790403 |pmc=8576238 |doi=10.21037/jgo-20-610 |url=}}</ref> | |||
**PD-1 expressed in nearly 70% of tumours.<ref name=pmid34790403/> | |||
==Sign out== | ==Sign out== | ||
Line 70: | Line 73: | ||
- INVASIVE SQUAMOUS CELL CARCINOMA. | - INVASIVE SQUAMOUS CELL CARCINOMA. | ||
</pre> | </pre> | ||
Notes: | |||
*There is no CAP Cancer Protocol Template. | |||
*AJCC staging is based on size of the tumour.<ref>URL: [https://www.cancer.org/cancer/types/anal-cancer/detection-diagnosis-staging/staging.html https://www.cancer.org/cancer/types/anal-cancer/detection-diagnosis-staging/staging.html]. Accessed on: June 26, 2023.</ref> | |||
==See also== | ==See also== |
edits